Here, this work shows that nuclear‐localized branched‐chain α‐ketoacid dehydrogenase kinase (BCKDK) acts as a modulator of HRR, promoting cell resistance against DNA damage‐inducing therapy in breast cancer. The gene discussed is BCKDK; the disease is breast carcinoma.